SourceBio International PLC Notice of Results (6721F)
23 March 2022 - 6:00PM
UK Regulatory
TIDMSBI
RNS Number : 6721F
SourceBio International PLC
23 March 2022
SourceBio International plc
("SourceBio", the "Company" or the "Group")
Notice of Results
Investor presentation
SourceBio International plc (AIM: SBI), the international
provider of integrated state-of- the-art laboratory services and
products , announces that its full year results for the year ended
31 December 2021 will be released on 5 April 2022.
Investor presentation
Jay LeCoque, Executive Chairman, and Tony Ratcliffe, Chief
Financial Officer, will provide a live presentation relating to the
Company's full year results via the Investor Meet Company platform
on Tuesday 5 April at 4.45 pm (BST). The presentation is open to
all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and add
to meet SourceBio International plc, via:
https://www.investormeetcompany.com/sourcebio-international-plc/register-investor
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of information already disclosed to the market
through regulatory notifications. A recording of the presentation,
a PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform afterwards.
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Adviser and Broker) Tel: 020 3100 2000
Bidhi Bhoma / Richard Lindley / William Hall
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07748 651 727
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products with clients in
the healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four businesses
areas:
-- Healthcare Diagnostics - histopathology cancer screening and
clinical diagnostic services for the NHS and private healthcare
providers across the UK and Ireland, including Digital
Pathology
-- Genomics - DNA sequencing services and Precision Medicine
offering for pharmaceutical and biotechnology companies, academia,
contract research organisations (CROs) and other research groups in
the UK, Europe and North America
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA
-- Infectious Disease Testing - a range of COVID-19 testing
services for commercial enterprises, private healthcare groups and
the NHS, including PCR testing under ISO 15189 accreditation.
SourceBio also provides employee testing solutions to industry,
direct to consumer home test kits and venue testing.
More details on Group operations can be found here:
www.sourcebioscience.com .
SourceBio International plc (SBI) is listed on the AIM market of
the London Stock Exchange.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORVLLFLLXLXBBX
(END) Dow Jones Newswires
March 23, 2022 03:00 ET (07:00 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024